Status:
SUSPENDED
Magnetocardiography Endocrine Registry
Lead Sponsor:
Genetesis Inc.
Conditions:
Endocrine Disorder
Eligibility:
All Genders
18+ years
Brief Summary
Endocrine disorders like Type 2 diabetes mellitus (T2DM) represent complex cardiometabolic disease processes affecting approximately 462 million individuals worldwide and is associated with a two- to ...
Eligibility Criteria
Inclusion
- ≥ 18 years of age at the time of enrollment
- Patients deemed at risk for cardiovascular disease from endocrine disorders
Exclusion
- \< 18 years of age
- Patients unable to fit into device
- Non-ambulatory patients
- Positive response(s) on CardioFlux Pre-Screening Form
- Patients with claustrophobia or unable to lie supine for five minutes
- Pregnant women
- Poor candidates for follow-up (e.g., no access to phone)
- Prisoners
Key Trial Info
Start Date :
December 14 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2030
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04739254
Start Date
December 14 2020
End Date
May 1 2030
Last Update
October 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Genetesis Facility
Mason, Ohio, United States, 45040